Lilly Q3: A Slow Start for Oral GLP-1 Makes the Peptide Capacity Bet Look Harder

Lilly reported Q3 2026 revenue of $24.397bn (+39% YoY) and $67.170bn for the first nine months (+46%). Tirzepatide (Mounjaro plus Zepbound) contributed $43.768bn, or 65% of total revenue; full-year guidance was raised from $85–87bn to $91–92bn, and the stock jumped 7.51% intraday, making Lilly the first pharmaceutical company to cross a $1.3trn market cap. Yet orforglipron (Foundayo), the oral small-molecule GLP-1 approved in April, booked only $184m in Q3 against expectations near $229m. A slower oral substitution curve extends the injectable franchise — and with it the payback window on peptide API and solid-phase synthesis capacity.

Lilly's Q3 2026 report, released before the open on 29 October, beat on both lines: revenue of $24.397bn (+39% YoY), net income of $6.451bn (+16%), and adjusted EPS of $7.48 against a consensus of $6.26. Nine-month revenue reached $67.170bn (+46%) with net income of $20.942bn (+50%). The company lifted full-year revenue guidance from $85–87bn to $91–92bn. The stock touched $1,404.37 intraday, up 7.51%, making Lilly the first pharmaceutical company to pass a $1.3trn valuation.

Three numbers that re-price GLP-1 tonnage

Mounjaro, the diabetes formulation, booked $10.723bn in the quarter (+65%), including roughly $5bn in the US, while sales outside the US grew 93%. Zepbound, the obesity formulation, added $5.352bn (+49%). Combined, tirzepatide reached $43.768bn for the nine months — 65% of Lilly's total revenue. A single molecule family at one company now exceeds the entire revenue of most multinational peers.

The geographic split is worth recording too: US $41.668bn (+36%), Europe $12.219bn (+44%), China $2.582bn (+75%), and other markets $8.854bn (+129%). China alone delivered $947m in Q3 (+69%). For CDMOs, that +129% in "other markets" means demand is spilling out of two mature geographies into many more jurisdictions — and each new jurisdiction implies its own registration, secondary packaging and eventually local fill-finish arrangement.

Oral did not take over; injectables are still accelerating

The most counterintuitive datapoint of the quarter is orforglipron (Foundayo), the first oral non-peptide GLP-1 agonist, approved in the US in April. It generated $184m in Q3 and $281m cumulatively since launching in Q2 — below the roughly $229m quarterly consensus tracked by StreetAccount.

That does not reverse the direction of oralisation, but it changes the slope. One popular narrative held that oral small molecules would absorb a meaningful share of the injectable market within three to five years, eroding long-term peptide API demand. Q3 suggests the substitution curve is flatter than assumed: adherence, efficacy ceilings and payer tiering all point to injectables and orals coexisting rather than swapping. Lilly is itself advancing retatrutide, a once-weekly triple agonist, whose readouts will keep demand anchored to the peptide modality.

The price-volume scissors are the real outsourcing driver

Another set of numbers deserves CDMO attention: US volume (prescriptions) grew 41%, but realised price fell 7%, so US revenue grew 34% to $15.1bn. Volume up, price down is the new normal after the 2025 pricing agreement with the White House.

For manufacturers this means gross profit per unit is compressing. As net price declines year after year, the return on capital of captive capacity falls and the relative appeal of outsourcing rises — but the driver shifts from "do you have capacity" to "are you cheaper than building it myself". That is a different logic from the 2025–26 capacity arms race, which was about certainty of supply. This phase rewards continuous flow, biocatalysis and industrial-scale solid-phase synthesis; it penalises players whose only argument is more reactor volume.

Four capacity linkages on the China side

Read against Chinese CDMO results, the mapping is unusually clean. WuXi AppTec's TIDES segment (peptides and oligonucleotides) posted RMB 11.52bn for the nine months (+46.9%), with full-year growth guidance raised to about 47% and solid-phase capacity moving from 100,000 to 130,000 litres. Asymchem expanded peptide capacity from 45,000 to 69,000 litres with further build planned beyond 2027. Jiuzhou Pharma added 20 TIDES projects in the first nine months, holds more than RMB 5bn in TIDES backlog, and lifted solid-phase peptide capacity 300% in H1. Samsung Biologics bought its way in, securing 87.92% of PolyPeptide to add peptide capability outside its 845,000-litre mammalian cell network.

A second supply-side signal comes from the customer side: at its 2026 capital markets day Novo Nordisk said it would source peptide API from contract manufacturers, breaking with vertical integration. When one of the two dominant GLP-1 sellers starts buying API externally, the addressable market for peptide manufacturing is redefined within a year.

Editor's note: a slower oral curve makes the capacity bet safer

Put three facts together — orals below expectations, injectables up 93% outside the US, and a $6bn guidance raise — and the option structure on peptide capacity changes. Had oral substitution arrived within three years, long-cycle, capital-heavy solid-phase synthesis and purification assets would face utilisation risk. A slower curve extends the injectable franchise, turning the payback from a bet on a date into a defensible range.

But the beneficiaries are not the same assets. Orforglipron is a small molecule outside the peptide route: it needs high-potency small-molecule API and complex oral solid dosage capability, not peptide synthesis. Tirzepatide is where the tonnage sits. If orals stay slow, peptides win; if orals break through, high-potency API and oral dosage forms win. Capital expenditure points in different directions, and betting on the wrong side shows up in utilisation after 2028.

The third variable is China. Up 75% for the nine months and 69% in Q3, China is Lilly's second-fastest growing region, and GLP-1 penetration there has barely started. What follows is local secondary packaging, local fill-finish and eventually local API supply — arguably a more accessible opportunity for domestic CDMOs than cross-border contracting, since approval pathways and customer relationships are shorter.